Karyopharm is committed to supporting independent research globally as part of the development process of Karyopharm investigational drug candidates. Independent research may be defined within the industry as Investigator Sponsored Research (ISR), Investigator Initiated Research (IIR), Investigator Sponsored Trials (IST) or Investigator Initiated Trials (IIT) and Outcomes Research (OR). Karyopharm considers all of the foregoing to be part of the Global Medical Research (GMR) program. The scientific and academic research communities may submit a proposal for Global Medical Research (GMR) through our online portal called PORE®. Karyopharm may provide support of independent research in the form of drug supply only or drug supply with funding. This program is open to physicians, researchers and institutions interested in conducting independent research.
Researchers interested in Karyopharm’s GMR program are required to first contact Karyopharm for a preliminary discussion of their research proposal. After your preliminary discussion with Karyopharm, we welcome you to submit your request via our PORE® Request Management System.
Through the Karyopharm internal review process, proposals are periodically reviewed for scientific merit and alignment with our clinical development strategy, among other factors. Karyopharm strives to provide a response to your application within 45 days of submission to PORE®. If, after internal review, the proposal is endorsed, we expect the applicant to provide a well-designed protocol to be submitted within 60 days of endorsement while supporting a rapid contracting process aiming to achieve start-up within 180 days of endorsement. Additional information regarding the submission requirements can be found within PORE®. You may also submit any further GMR related questions at GMR@karyopharm.com.
Submission of a proposal does not imply nor guarantee endorsement. Any support of a proposal to be provided by Karyopharm is contingent upon an executed research agreement and the terms therein.